Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of human von Willebrand factor for treatment of spontaneous and traumatic bleeding in adolescents and adults with von Willebrand disease
CTR20223118Phase 3Active
- Sponsor
- China Resources Boya Bio-pharmaceutical Group
- Start
- Dec 2022
- Countries
- 1
01
Overview
A Phase 3 trial of von Willebrand factor concentrate in von Willebrand disease (VWD), sponsored by China Resources Boya Bio-pharmaceutical Group. Started Dec 2022; status: active.
02
Drugs
von Willebrand factor concentrate
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on CTR20223118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223118.